Top Markets
#1 MowCat MowCat +49.01%
#2 Velvet Velvet +30.09%
#3 Audiera Audiera +24.96%
#4 Derive Derive +21.35%
#5 MarsCoin MarsCoin +19.01%
#6 Quack AI Quack AI +16.51%
#7 Biconomy Biconomy +16.11%
#8 Cross Cross +13.11%
#9 Geodnet Geodnet +12.29%
#10 The Bitcoin Bull The Bitcoin Bull +9.59%
Coin of the day
MowCat MowCat
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc.

QLGN
Classifica tra le azioni #35381
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing... Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a patient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.
Prezzo delle azioni
$2.37
Ultima sincronizzazione: 2025-12-15
Capitalizzazione di mercato
$3.99M
Variazione (1 giorno)
-5.58%
Variazione (1 anno)
24.74%
Paese
US
Scambia Qualigen Therapeutics, Inc. (QLGN)

Categoria

Healthcare
Rapporto P/B per Qualigen Therapeutics, Inc. (QLGN)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Qualigen Therapeutics, Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Qualigen Therapeutics, Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE